Lugene Eye Institute
 
Print This Page

Email This Page
Why Choose Us?
 
Why Choose Us?  
Doctors Home  
Our Technology  
News  
Clinical Studies  
CareCredit  
Insurance, Medical Group & IPA Affiliations  
Insurance Accepted  
Affiliated IPA's & Medical Groups  

WHY CHOOSE US?



 

Clinical Studies

The EyeRely Pink Eye Clinical Research Trial

Our practice is taking part in this trial as part of our continued commitment to investigating new treatment options for our patients. The EyeRely clinical research trial will evaluate the safety and effectiveness of a new investigational medication for pink eye (bacterial conjunctivitis).
 
Eligible Participants: 

Infected with pink eye (beginning within the past four days).  Symptoms include red, irritated eyes, pus or mucus-like discharge, matted or crusted eyelids. 1 month of age or older.
 
Key facts about EyeRely:

  • No cost: All Study-related medication and physician evaluations will be provided at no cost. And patient will receive the study medication immediately because no prescription is required.
  • Reimbursement: Patient will be reimbursed for time and travel.
  • Physician evaluation: A comprehensive eye evaluation will be conducted by the specialist.
  • Short Duration: The trial will involve 3 scheduled office visits over 4-5 days.
  • No appointment needed: Patient may come to the clinic anytime during clinic hours.

For more information contact:

Jasmine Santons
Practice Administrator
801 S. Chevy Chase Dr., Suite 103
Glendale, CA 91205-4437
PH: 818-265-2255 / Fax: 818-507-5027
Click here to Email

For more information about Clinical Studies at Lugene Eye Institute, contact us at 818-265-2255, or Click Here to contact us via email.

Thank you!

  

VISIT US AT: 801 S. Chevy Chase Dr., Suite 103 Glendale, CA 91205-4437
PH: 818-265-2255 / Fax: 818-507-5027
EMAIL: services@lugeneeye.com

Mojo Interactive Programming, Design and Hosting by Mojo Interactive, © 2002-2010.
Content © 2002-2010 Patient Education Concepts, Inc. Licensed Users Only
PEC back to top ^